Annoucement of ATL1103 Phase 2 trials with its details and funding is a no brainer. We are 100% sure it will happen sooner than later.
ATL1103 for cancer is a big bonus. Otherwise, it won't distract the current target of sight disorder and acromegaly.
Annoucement for the pharma that is doing DD is also a certainty, it could well be that ATL1103 is not for licensing until after Phase 2a in order to get better deal or the pharma is confident enough to offer a sweet deal before Phase 2a. Let's see how it pans out. Either way, some news will come soon.
ATL1101 for prostate cancer is not a wild card since it is already on the card. Afandin said so that there is interest in doing a deal.
Reactivate ATL1102 for MS with TEVA is a wild card, I must admit.
ATL1102 for stem cells is actually quite promising.
Unlike traditional drug trials targeting protein of diseases, with the known Human Genome Sequencing and the known 12 mechanisms of Antisense (accroding to ISIS), the 2nd Gen Antisense compounds can actually be trialed and modified in a much faster timeline.
Also 2nd Gen antisense is 10 times more potent that its currently available drugs.
I believe the competition to market for 2nd Gen antisense drugs is hotting up in 2012. Because this will be the first year we will see the first 2nd gen antisense drug to market (Mipomersen) and Pfizer did the first deal in antisense licensing (Excalliard).
Other top 20 pharmas will certainly be jostling for position in Antisense R & D companies. ANP is in fact in the forefront of Antisense R&D with 3 compounds with possibly 5 targets.
Biotech could be the sector that can weather the volatile market given its own timeline in drug developments and the possible exponential growth value.
May be luck will be on our side.
- Forums
- ASX - By Stock
- anticipated announcements - q1 2012
PER
percheron therapeutics limited
Add to My Watchlist
10.5%
!
0.9¢

Annoucement of ATL1103 Phase 2 trials with its details and...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
0.9¢ |
Change
-0.001(10.5%) |
Mkt cap ! $9.243M |
Open | High | Low | Value | Volume |
0.9¢ | 0.9¢ | 0.9¢ | $17.69K | 1.974M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
11 | 4868299 | 0.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.9¢ | 1969872 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
11 | 4868299 | 0.008 |
3 | 1285714 | 0.007 |
1 | 1000000 | 0.006 |
2 | 3999997 | 0.005 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.009 | 1969872 | 4 |
0.010 | 1993383 | 7 |
0.011 | 2042858 | 5 |
0.012 | 2658324 | 5 |
0.013 | 691461 | 3 |
Last trade - 15.45pm 03/07/2025 (20 minute delay) ? |
Featured News
PER (ASX) Chart |
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Matthew Kowal / Andy Burger, CCO / Head of E-Commerce
Matthew Kowal / Andy Burger
CCO / Head of E-Commerce
SPONSORED BY The Market Online